Effects of Ganoderic acid Me on inhibiting multidrug resistance and inducing apoptosis in multidrug resistant colon cancer cells

Process Biochemistry

Volumn 46, Issue 6, 2011, Pages 1307-1314

  Jiang, Zijing ^a   Jin, Tiantian ^a   Gao, Feng ^a   Liu, Jianwen ^a   Zhong, Jianjiang ^b   Zhao, Heng ^c  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Shanghai Jiao Tong University   (China)

^c SHANGHAI CHEST HOSPITAL   (China)

Author keywords

Apoptosis; Ganoderic acid Me; MDR1; MRPs; Multidrug resistance

Indexed keywords

APOPTOSIS; GANODERIC ACID ME; MDR1; MRPS; MULTIDRUG RESISTANCE;

CELL DEATH; CELL MEMBRANES; CLONING; DISEASES; LEAD COMPOUNDS;

CLONE CELLS;

FUNGI; GANODERMA LUCIDUM;

EID: 79955608537     PISSN: 13595113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.procbio.2011.02.023     Document Type: Article

References (39)

1. Mizuno T, Wang G, Zhang J, Kawagishi H, Nishitoba T, Reishi LJ. Ganoderma lucidum and Ganoderma tsugae: bioactive substances and medicinal effects. Food Rev Int 1995;11:151-66.
2. Lin SB, Li CH, Lee SS, Kan LS. Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest. Life Sci 2003;72:2381-90.
3. Tang W, Liu JW, Zhao WM, Wei DZ, Zhong JJ. Ganoderic acid T from Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung cancer cells. Life Sci 2006;80:205-11. (Pubitemid 44853986)
4. Xu K, Liang X, Gao F, Zhong JJ, Liu JW. Antimetastatic effect of ganoderic acid T in vitro through inhibition of cancer cell invasion. Process Biochem 2010;45:1261-7.
5. Tang W, Gu TY, Zhong JJ. Separation of targeted ganoderic acids from Ganoderma lucidum by reversed phase liquid chromatography with ultraviolet and mass spectrometry detections. Biochem Eng J 2006;32:205-10. (Pubitemid 44751583)
6. Wang G, Zhao J, Liu JW, Huang YP, Zhong JJ, Tang W. Enhancement of IL-2 and IFN-γ expression and NK cells activity involved in the antitumor effect of ganoderic acid Me in vivo. Int Immunopharmacol 2007;7:864-70. (Pubitemid 46635284)
7. Chen NH, Zhong JJ. Ganoderic acid Me induces G1 arrest in wild-type p53 human tumor cells while G1/S transition arrest in p53-null cells. Process Biochem 2009;44:928-33.
8. Gotttesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58. (Pubitemid 37328807)
9. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003;8:411-24. (Pubitemid 37238869)
10. Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene 2003;22:7512-23. (Pubitemid 37487173)
11. Pakunlu RI, Wang Y, Tsao W, Pozharov V, Cook TJ, Minko T. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Cancer Res 2004;64:6214-24. (Pubitemid 39129423)
12. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58:931-59. (Pubitemid 32652819)
13. Szakacs G, Annereau JP, Lababidi S, Shankavram U, Arciello A, Bussey KJ, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004;6:129-37. (Pubitemid 39485685)
14. Deeley RG, Cole SP. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett 2006;580:1103-11. (Pubitemid 43185290)
15. Minko T, Dharap SS, Pakunlu RI, Wang Y. Molecular targeting of drug delivery systems to cancer. Curr Drug Targets 2004;5:389-406. (Pubitemid 38559349)
16. Hsiao YM, Huang YL, Tang SC, Shieh GJ, Lai JY, Wang PH, et al. Effect of a fungal immunomodulatory protein from Ganoderma tsugae on cell cycle and interferon-gamma production through phosphatidylinositol 3-kinase signal pathway. Process Biochem 2008;43:423-30.
17. Mareel M, Leroy A. Clinical cellular and molecular aspects of cancer invasion. Phys Rev Lett 2003;83:337-76. (Pubitemid 36382891)
18. Zhang J, Shen YL, Liu JW, Wei DZ. Antimetastatic effect of prodigiosin through inhibition of tumor invasion. Biochem Pharmacol 2005;69:407-14. (Pubitemid 40094501)
19. Xu YC, Xu GL, Liu L, Xu DS, Liu JW. Anti-invasion effect of rosmarinic acid via the extracellular signal-regulated kinase and oxidation-reduction pathway in Ls174-T cells. J Cell Biochem 2010;111:370-9.
20. Wang G, Chen HF, Huang MH, Wang NL, Zhang JC, Zhang YO, et al. Methyl protodioscin induces G2/M cell cycle arrest and apoptosis in HepG2 liver cancer cells. Cancer Lett 2006;241:102-9.
21. Verma M, Singh SK, Bhushan S, Sharma VK, Datt P, Kapahi BK, et al. In vitro cytotoxic potential of Polyalthia longifolia on human cancer cell lines and induction of apoptosis through mitochondrial-dependent pathway in HL60 cells. Chem Biol Interact 2008;71:45-56.
22. Zamzami N, Maisse C, Metivier D, Kroemer G. Measurement of membrane permeability and permeability transition of mitochondria. Method Cell Biol 2001;65:147-58.
23. Liu Y, Zhang SP, Cai YQ. Cytoprotective effects of selenium on cadmium-induced LLC-PK1 cells apoptosis by activating JNK pathway. Toxicol In Vitro 2007;21:677-84. (Pubitemid 46550757)
24. Pakunlu RI, Wang Y, Saad M, Khandare JJ, Starovoytov V, Minko T. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release 2006;114:153-62.
25. Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res 1994;54:4676-9. (Pubitemid 24276493)
26. Sonneveld P, Wiemer E. Inhibitors of multidrug resistance. Curr Opin Oncol 1997;9:543-8. (Pubitemid 27480857)
27. Lania L, Majello B, De Luca P. Transcriptional regulation by the Sp family proteins. Int J Biochem Cell B 1997;29:1313-23. (Pubitemid 28153485)
28. Takane H, Kobayashi D, Hirota T, Kigawa J, Terakawa N, Otsubo K, et al. Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J Pharmacol and Exp Ther 2004;311:1179-87. (Pubitemid 39612726)
29. Daschner PJ, Ciolino HP, Plouzek CA, Yeh GC. Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells. Breast Cancer Res Treat 1999;53:229-40. (Pubitemid 29209892)
30. Marilyn MM, Smith DE. A signal transduction pathway for activation of the MDRl promoter involves the proto-oncogene c-ruf kinase. J Biol Chem 1993;21:15347-50. (Pubitemid 23222019)
31. Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 2003;4:721-9. (Pubitemid 37527207)
32. Green DR. Apoptotic pathways: the roads to run. Cell 1998;94:695-8.
33. Andrew M. Cyclin ubiquitination: the destructive end of mitosis. Cell 1995;81:149-52.
34. Antonsson B, Martinou JC. The Bcl-2 protein family. Exp Cell Res 2000;256:50-7. (Pubitemid 30211166)
35. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997;387:773-6. (Pubitemid 27270895)
36. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;326:1-16. (Pubitemid 27386911)
37. Ashkenazi A, Dixit VM. Death receptor: signaling and modulation. Science 1998;281:1305-8.
38. Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 2002;14:86-91. (Pubitemid 34072969)
39. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000;14:289-300. (Pubitemid 30106484)